Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Jan 11:11:67-69.
doi: 10.1016/j.ebcr.2019.01.001. eCollection 2019.

Perampanel in lissencephaly-associated epilepsy

Satoru Ikemoto  1   2 , Shin-Ichiro Hamano  1   3 , Yuko Hirata  1   2 , Ryuki Matsuura  1 , Reiko Koichihara  3
Affiliations
Case Reports

Perampanel in lissencephaly-associated epilepsy

Satoru Ikemoto et al. Epilepsy Behav Case Rep. .

Abstract

We retrospectively investigated whether perampanel (PER) could serve as an alternative for treating drug-resistant seizures in lissencephaly. We investigated the following data: age at onset of epilepsy, age at start of PER, etiology, brain MRI findings, seizure type, seizure frequency, adverse effects, and concomitant anti-epileptic drugs. There were 5 patients with lissencephaly, including 2 with Miller-Dieker syndrome. Four out of five patients exhibited ≥ 50% seizure reduction. Myoclonic seizures disappeared in 1 patient. PER was an effective adjunctive anti-seizure drug in our series of patients with lissencephaly.

Keywords: AMPA, alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid; DRPLA, dentatorubral–pallidoluysian atrophy; GTCS, generalized tonic–clonic seizures; Lissencephaly; NMDA, N-methyl-d-aspartate; Neuronal migration disorder; PER, perampanel; Perampanel.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Representative brain magnetic resonance imaging (MRI) findings in T2-weighted images. Each number indicates patient number in Table 1.
See this image and copyright information in PMC

References

    1. Rogawski M.A. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr. 2011;11:56–63. - PMC - PubMed
    1. Goldsmith D., Minassian B.A. Efficacy and tolerability of perampanel in ten patients with Lafora disease. Epilepsy Behav. 2016;62:132–135. - PMC - PubMed
    1. Shiraishi H. Efficacy of perampanel for controlling seizures and improving neurological dysfunction in a patient with dentatorubral–pallidoluysian atrophy (DRPLA) Epilepsy Behav Case Rep. 2017;8:44–46. - PMC - PubMed
    1. Crespel A., Gelisse P., Tang N.P., Genton P. Perampanel in 12 patients with Unverricht–Lundborg disease. Epilepsia. 2017;58:543–547. - PubMed
    1. Fogli A., Guerrini R., Moro F., Fernandez-Alvarez E., Livet M.O., Renieri A. Intracellular levels of the LIS1 protein correlate with clinical and neuroradiological findings in patients with classical lissencephaly. Ann Neurol. 1999;45:154–161. - PubMed

Publication types

LinkOut - more resources